66623-22-1

Upstream product

• 1336-21-6 ammonium hydroxide 
• 162010-70-0 (2-Amino-5-methylpyrid-3-yl)sulfonyl chloride 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 

Downstream Products

• 1298029-87-4 [2-(4-bromo-2-fluorobenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-88-5 [2-(3-nitrobenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-89-6 [2-(4-(trifluoromethyl)benzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-90-9 [2-(2,4,5-trifluorobenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298029-91-0 [2-(4-methoxybenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid methyl ester 
• 1298030-01-9 [2-(4-bromo-2-fluorobenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298030-02-0 [2-(3-nitrobenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298030-03-1 [2-(4-(trifluoromethyl)benzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298030-04-2 [2-(2,4,5-trifluorobenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 
• 1298030-05-3 [2-(4-methoxybenzyl)-7-methyl-3,4-dihydro-2H-pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxid-4-yl] acetic acid 

Relevant academic research and scientific papers

Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold

A series of pyrido[2,3-e]-[1,2,4]-thiadiazine 1,1-dioxide acetic acid derivatives were synthesized and tested for their inhibitory activity against aldose reductase (ALR2). These derivatives were found to be potent aldose reductase inhibitors with IC

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Anti-infective agents

The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HC

Anti-infective agents

Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Non-peptidic angiotensin-II-receptor-antagonists

Novel compounds having the formula STR1 wherein R 1, R 2, X and Y are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.